Core Viewpoint - Hualu Bio experienced a decline of 4.84% on November 21, with a trading volume of 68.287 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On November 21, Hualu Bio had a financing buy-in amount of 5.8958 million yuan and a financing repayment of 5.9855 million yuan, resulting in a net financing buy of -89,700 yuan [1] - As of November 21, the total financing and securities lending balance for Hualu Bio was 46.253 million yuan, which represents 2.25% of its circulating market value, indicating a low financing balance compared to the past year [1] - The company had no securities lending activity on November 21, with a lending balance of 0.00 shares, which is at a high level compared to the past year [1] Business Performance - As of September 30, Hualu Bio reported a total of 10,300 shareholders, a decrease of 9.42% from the previous period, while the average circulating shares per person increased by 11.88% to 9,132 shares [2] - For the period from January to September 2025, Hualu Bio achieved an operating income of 868 million yuan, representing a year-on-year growth of 17.98%, and a net profit attributable to shareholders of 16.3335 million yuan, which is a significant increase of 146.55% year-on-year [2] Dividend Information - Since its A-share listing, Hualu Bio has distributed a total of 76.7904 million yuan in dividends, with 46.4484 million yuan distributed over the past three years [3] - As of September 30, 2025, among the top ten circulating shareholders, the Noan Multi-Strategy Mixed A fund entered as the sixth-largest shareholder with 1.0993 million shares, while the CITIC Prudential Multi-Strategy Mixed A fund exited the top ten list [3]
华绿生物11月21日获融资买入589.58万元，融资余额4625.30万元